APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antihyperuricemic Agents

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Antihyperuricemic Agents Industry Growth and Trends Forecast to 2032

29 December 2025126 pages

Choose your research edition.

Industry ResearchAntihyperuricemic Agents Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Antihyperuricemic Agents Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Antihyperuricemic Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antihyperuricemic Agents Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Antihyperuricemic Agents Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Antihyperuricemic Agents market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Antihyperuricemic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Antihyperuricemic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antihyperuricemic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antihyperuricemic Agents include Accord Healthcare, ALP Pharm, APOTEX, Casper Pharma, Dr. Reddys Laboratories, Gentec Pharmaceutical Group, Hikma, Indoco Remedies and Ipca Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Antihyperuricemic Agents market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Antihyperuricemic Agents market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antihyperuricemic Agents market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antihyperuricemic Agents.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Antihyperuricemic Agents market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Antihyperuricemic Agents Market by Company

Accord Healthcare

ALP Pharm

APOTEX

Casper Pharma

Dr. Reddys Laboratories

Gentec Pharmaceutical Group

Hikma

Indoco Remedies

Ipca Laboratories

Lupin

Medinova

NorthStar Healthcare

Odan Laboratories

Rhea Pharmaceutical

TEIJIN

Waterstone Pharmaceuticals

West Ward Pharmaceuticals

Wockhardt

Zydus Pharmaceuticals

Beijing Jialin Pharmaceutical

Hangzhou Zhuyangxin Pharmaceutical

Jiangsu Hengrui Medicine

Jiangsu Wanbang Biopharmaceuticals

KPC Pharmaceuticals

Mylan

Sun Pharmaceutical

Teva

Tonghua Limin

Takeda Pharmaceuticals

YiChang HEC ChangJiang Pharmaceutical

Antihyperuricemic Agents Segment by Type

Inhibit Uric Acid Production Agents

Promote Uric Acid Excretion Agents

Others

Antihyperuricemic Agents Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Antihyperuricemic Agents Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antihyperuricemic Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antihyperuricemic Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antihyperuricemic Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antihyperuricemic Agents manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Antihyperuricemic Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Inhibit Uric Acid Production Agents Table 2. Major Company of Promote Uric Acid Excretion Agents Table 3. Major Company of Others Table 4. Global Antihyperuricemic Agents Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Antihyperuricemic Agents Sales by Type (2021-2026) & (K Units) Table 6. Global Antihyperuricemic Agents Sales Market Share in Volume by Type (2021-2026) Table 7. Global Antihyperuricemic Agents Sales by Type (2021-2026) & (US$ Million) Table 8. Global Antihyperuricemic Agents Sales Market Share in Value by Type (2021-2026) Table 9. Global Antihyperuricemic Agents Price by Type (2021-2026) & (US$/Unit) Table 10. Global Antihyperuricemic Agents Sales by Type (2027-2032) & (K Units) Table 11. Global Antihyperuricemic Agents Sales Market Share in Volume by Type (2027-2032) Table 12. Global Antihyperuricemic Agents Sales by Type (2027-2032) & (US$ Million) Table 13. Global Antihyperuricemic Agents Sales Market Share in Value by Type (2027-2032) Table 14. Global Antihyperuricemic Agents Price by Type (2027-2032) & (US$/Unit) Table 15. North America Antihyperuricemic Agents Sales by Type (2021-2026) & (K Units) Table 16. North America Antihyperuricemic Agents Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Antihyperuricemic Agents Sales by Type (2021-2026) & (K Units) Table 18. Europe Antihyperuricemic Agents Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Antihyperuricemic Agents Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Antihyperuricemic Agents Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Antihyperuricemic Agents Sales by Type (2021-2026) & (K Units) Table 22. Latin America Antihyperuricemic Agents Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Antihyperuricemic Agents Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Antihyperuricemic Agents Sales by Type (2021-2026) & (US$ Million) Table 25. Antihyperuricemic Agents Industry Trends Table 26. Antihyperuricemic Agents Industry Drivers Table 27. Antihyperuricemic Agents Industry Opportunities and Challenges Table 28. Antihyperuricemic Agents Industry Restraints Table 29. Global Antihyperuricemic Agents Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Antihyperuricemic Agents Revenue Market Share by Company (2021-2026) Table 31. Global Antihyperuricemic Agents Sales by Company (2021-2026) & (K Units) Table 32. Global Antihyperuricemic Agents Sales Share by Company (2021-2026) Table 33. Global Antihyperuricemic Agents Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Antihyperuricemic Agents Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Antihyperuricemic Agents Major Company Production Sites and Headquarters Table 36. Global Antihyperuricemic Agents Company, Product Type & Application Table 37. Global Antihyperuricemic Agents Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Antihyperuricemic Agents by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Antihyperuricemic Agents Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Antihyperuricemic Agents Sales by Region (2021-2026) & (K Units) Table 42. Global Antihyperuricemic Agents Sales Market Share in Volume by Region (2021-2026) Table 43. Global Antihyperuricemic Agents Sales by Region (2021-2026) & (US$ Million) Table 44. Global Antihyperuricemic Agents Sales Market Share in Value by Region (2021-2026) Table 45. Global Antihyperuricemic Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Antihyperuricemic Agents Sales by Region (2027-2032) & (K Units) Table 47. Global Antihyperuricemic Agents Sales Market Share in Volume by Region (2027-2032) Table 48. Global Antihyperuricemic Agents Sales by Region (2027-2032) & (US$ Million) Table 49. Global Antihyperuricemic Agents Sales Market Share in Value by Region (2027-2032) Table 50. Global Antihyperuricemic Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Antihyperuricemic Agents Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Antihyperuricemic Agents Sales by Application (2021-2026) & (K Units) Table 53. Global Antihyperuricemic Agents Sales Market Share in Volume by Application (2021-2026) Table 54. Global Antihyperuricemic Agents Sales by Application (2021-2026) & (US$ Million) Table 55. Global Antihyperuricemic Agents Sales Market Share in Value by Application (2021-2026) Table 56. Global Antihyperuricemic Agents Price by Application (2021-2026) & (US$/Unit) Table 57. Global Antihyperuricemic Agents Sales by Application (2027-2032) & (K Units) Table 58. Global Antihyperuricemic Agents Sales Market Share in Volume by Application (2027-2032) Table 59. Global Antihyperuricemic Agents Sales by Application (2027-2032) & (US$ Million) Table 60. Global Antihyperuricemic Agents Sales Market Share in Value by Application (2027-2032) Table 61. Global Antihyperuricemic Agents Price by Application (2027-2032) & (US$/Unit) Table 62. North America Antihyperuricemic Agents Sales by Application (2021-2026) & (K Units) Table 63. North America Antihyperuricemic Agents Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Antihyperuricemic Agents Sales by Application (2021-2026) & (K Units) Table 65. Europe Antihyperuricemic Agents Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Antihyperuricemic Agents Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Antihyperuricemic Agents Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Antihyperuricemic Agents Sales by Application (2021-2026) & (K Units) Table 69. Latin America Antihyperuricemic Agents Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Antihyperuricemic Agents Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Antihyperuricemic Agents Sales by Application (2021-2026) & (US$ Million) Table 72. Accord Healthcare Company Information Table 73. Accord Healthcare Business Overview Table 74. Accord Healthcare Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Accord Healthcare Antihyperuricemic Agents Product Portfolio Table 76. Accord Healthcare Recent Development Table 77. ALP Pharm Company Information Table 78. ALP Pharm Business Overview Table 79. ALP Pharm Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. ALP Pharm Antihyperuricemic Agents Product Portfolio Table 81. ALP Pharm Recent Development Table 82. APOTEX Company Information Table 83. APOTEX Business Overview Table 84. APOTEX Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. APOTEX Antihyperuricemic Agents Product Portfolio Table 86. APOTEX Recent Development Table 87. Casper Pharma Company Information Table 88. Casper Pharma Business Overview Table 89. Casper Pharma Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Casper Pharma Antihyperuricemic Agents Product Portfolio Table 91. Casper Pharma Recent Development Table 92. Dr. Reddys Laboratories Company Information Table 93. Dr. Reddys Laboratories Business Overview Table 94. Dr. Reddys Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Dr. Reddys Laboratories Antihyperuricemic Agents Product Portfolio Table 96. Dr. Reddys Laboratories Recent Development Table 97. Gentec Pharmaceutical Group Company Information Table 98. Gentec Pharmaceutical Group Business Overview Table 99. Gentec Pharmaceutical Group Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Gentec Pharmaceutical Group Antihyperuricemic Agents Product Portfolio Table 101. Gentec Pharmaceutical Group Recent Development Table 102. Hikma Company Information Table 103. Hikma Business Overview Table 104. Hikma Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Hikma Antihyperuricemic Agents Product Portfolio Table 106. Hikma Recent Development Table 107. Indoco Remedies Company Information Table 108. Indoco Remedies Business Overview Table 109. Indoco Remedies Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Indoco Remedies Antihyperuricemic Agents Product Portfolio Table 111. Indoco Remedies Recent Development Table 112. Ipca Laboratories Company Information Table 113. Ipca Laboratories Business Overview Table 114. Ipca Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Ipca Laboratories Antihyperuricemic Agents Product Portfolio Table 116. Ipca Laboratories Recent Development Table 117. Lupin Company Information Table 118. Lupin Business Overview Table 119. Lupin Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Lupin Antihyperuricemic Agents Product Portfolio Table 121. Lupin Recent Development Table 122. Medinova Company Information Table 123. Medinova Business Overview Table 124. Medinova Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Medinova Antihyperuricemic Agents Product Portfolio Table 126. Medinova Recent Development Table 127. NorthStar Healthcare Company Information Table 128. NorthStar Healthcare Business Overview Table 129. NorthStar Healthcare Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. NorthStar Healthcare Antihyperuricemic Agents Product Portfolio Table 131. NorthStar Healthcare Recent Development Table 132. Odan Laboratories Company Information Table 133. Odan Laboratories Business Overview Table 134. Odan Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Odan Laboratories Antihyperuricemic Agents Product Portfolio Table 136. Odan Laboratories Recent Development Table 137. Rhea Pharmaceutical Company Information Table 138. Rhea Pharmaceutical Business Overview Table 139. Rhea Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Rhea Pharmaceutical Antihyperuricemic Agents Product Portfolio Table 141. Rhea Pharmaceutical Recent Development Table 142. TEIJIN Company Information Table 143. TEIJIN Business Overview Table 144. TEIJIN Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. TEIJIN Antihyperuricemic Agents Product Portfolio Table 146. TEIJIN Recent Development Table 147. Waterstone Pharmaceuticals Company Information Table 148. Waterstone Pharmaceuticals Business Overview Table 149. Waterstone Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Waterstone Pharmaceuticals Antihyperuricemic Agents Product Portfolio Table 151. Waterstone Pharmaceuticals Recent Development Table 152. West Ward Pharmaceuticals Company Information Table 153. West Ward Pharmaceuticals Business Overview Table 154. West Ward Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. West Ward Pharmaceuticals Antihyperuricemic Agents Product Portfolio Table 156. West Ward Pharmaceuticals Recent Development Table 157. Wockhardt Company Information Table 158. Wockhardt Business Overview Table 159. Wockhardt Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Wockhardt Antihyperuricemic Agents Product Portfolio Table 161. Wockhardt Recent Development Table 162. Zydus Pharmaceuticals Company Information Table 163. Zydus Pharmaceuticals Business Overview Table 164. Zydus Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Zydus Pharmaceuticals Antihyperuricemic Agents Product Portfolio Table 166. Zydus Pharmaceuticals Recent Development Table 167. Beijing Jialin Pharmaceutical Company Information Table 168. Beijing Jialin Pharmaceutical Business Overview Table 169. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 170. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Portfolio Table 171. Beijing Jialin Pharmaceutical Recent Development Table 172. Hangzhou Zhuyangxin Pharmaceutical Company Information Table 173. Hangzhou Zhuyangxin Pharmaceutical Business Overview Table 174. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 175. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Portfolio Table 176. Hangzhou Zhuyangxin Pharmaceutical Recent Development Table 177. Jiangsu Hengrui Medicine Company Information Table 178. Jiangsu Hengrui Medicine Business Overview Table 179. Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 180. Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Portfolio Table 181. Jiangsu Hengrui Medicine Recent Development Table 182. Jiangsu Wanbang Biopharmaceuticals Company Information Table 183. Jiangsu Wanbang Biopharmaceuticals Business Overview Table 184. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 185. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Portfolio Table 186. Jiangsu Wanbang Biopharmaceuticals Recent Development Table 187. KPC Pharmaceuticals Company Information Table 188. KPC Pharmaceuticals Business Overview Table 189. KPC Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 190. KPC Pharmaceuticals Antihyperuricemic Agents Product Portfolio Table 191. KPC Pharmaceuticals Recent Development Table 192. Mylan Company Information Table 193. Mylan Business Overview Table 194. Mylan Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 195. Mylan Antihyperuricemic Agents Product Portfolio Table 196. Mylan Recent Development Table 197. Sun Pharmaceutical Company Information Table 198. Sun Pharmaceutical Business Overview Table 199. Sun Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 200. Sun Pharmaceutical Antihyperuricemic Agents Product Portfolio Table 201. Sun Pharmaceutical Recent Development Table 202. Teva Company Information Table 203. Teva Business Overview Table 204. Teva Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 205. Teva Antihyperuricemic Agents Product Portfolio Table 206. Teva Recent Development Table 207. Tonghua Limin Company Information Table 208. Tonghua Limin Business Overview Table 209. Tonghua Limin Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 210. Tonghua Limin Antihyperuricemic Agents Product Portfolio Table 211. Tonghua Limin Recent Development Table 212. Takeda Pharmaceuticals Company Information Table 213. Takeda Pharmaceuticals Business Overview Table 214. Takeda Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 215. Takeda Pharmaceuticals Antihyperuricemic Agents Product Portfolio Table 216. Takeda Pharmaceuticals Recent Development Table 217. YiChang HEC ChangJiang Pharmaceutical Company Information Table 218. YiChang HEC ChangJiang Pharmaceutical Business Overview Table 219. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 220. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Portfolio Table 221. YiChang HEC ChangJiang Pharmaceutical Recent Development Table 222. North America Antihyperuricemic Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 223. North America Antihyperuricemic Agents Sales by Country (2021-2026) & (K Units) Table 224. North America Antihyperuricemic Agents Sales Market Share by Country (2021-2026) Table 225. North America Antihyperuricemic Agents Sales Forecast by Country (2027-2032) & (K Units) Table 226. North America Antihyperuricemic Agents Sales Market Share Forecast by Country (2027-2032) Table 227. North America Antihyperuricemic Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 228. North America Antihyperuricemic Agents Market Size by Country (2021-2026) & (US$ Million) Table 229. North America Antihyperuricemic Agents Market Share by Country (2021-2026) Table 230. North America Antihyperuricemic Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 231. North America Antihyperuricemic Agents Market Share Forecast by Country (2027-2032) Table 232. Europe Antihyperuricemic Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 233. Europe Antihyperuricemic Agents Sales by Country (2021-2026) & (K Units) Table 234. Europe Antihyperuricemic Agents Sales Market Share by Country (2021-2026) Table 235. Europe Antihyperuricemic Agents Sales Forecast by Country (2027-2032) & (K Units) Table 236. Europe Antihyperuricemic Agents Sales Market Share Forecast by Country (2027-2032) Table 237. Europe Antihyperuricemic Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 238. Europe Antihyperuricemic Agents Market Size by Country (2021-2026) & (US$ Million) Table 239. Europe Antihyperuricemic Agents Market Share by Country (2021-2026) Table 240. Europe Antihyperuricemic Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 241. Europe Antihyperuricemic Agents Market Share Forecast by Country (2027-2032) Table 242. Asia-Pacific Antihyperuricemic Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 243. Asia-Pacific Antihyperuricemic Agents Sales by Country (2021-2026) & (K Units) Table 244. Asia-Pacific Antihyperuricemic Agents Sales Market Share by Country (2021-2026) Table 245. Asia-Pacific Antihyperuricemic Agents Sales Forecast by Country (2027-2032) & (K Units) Table 246. Asia-Pacific Antihyperuricemic Agents Sales Market Share Forecast by Country (2027-2032) Table 247. Asia-Pacific Antihyperuricemic Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 248. Asia-Pacific Antihyperuricemic Agents Market Size by Country (2021-2026) & (US$ Million) Table 249. Asia-Pacific Antihyperuricemic Agents Market Share by Country (2021-2026) Table 250. Asia-Pacific Antihyperuricemic Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 251. Asia-Pacific Antihyperuricemic Agents Market Share Forecast by Country (2027-2032) Table 252. Latin America Antihyperuricemic Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 253. Latin America Antihyperuricemic Agents Sales by Country (2021-2026) & (K Units) Table 254. Latin America Antihyperuricemic Agents Sales Market Share by Country (2021-2026) Table 255. Latin America Antihyperuricemic Agents Sales Forecast by Country (2027-2032) & (K Units) Table 256. Latin America Antihyperuricemic Agents Sales Market Share Forecast by Country (2027-2032) Table 257. Latin America Antihyperuricemic Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 258. Latin America Antihyperuricemic Agents Market Size by Country (2021-2026) & (US$ Million) Table 259. Latin America Antihyperuricemic Agents Market Share by Country (2021-2026) Table 260. Latin America Antihyperuricemic Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 261. Latin America Antihyperuricemic Agents Market Share Forecast by Country (2027-2032) Table 262. Middle East and Africa Antihyperuricemic Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 263. Middle East and Africa Antihyperuricemic Agents Sales by Country (2021-2026) & (K Units) Table 264. Middle East and Africa Antihyperuricemic Agents Sales Market Share by Country (2021-2026) Table 265. Middle East and Africa Antihyperuricemic Agents Sales Forecast by Country (2027-2032) & (K Units) Table 266. Middle East and Africa Antihyperuricemic Agents Sales Market Share Forecast by Country (2027-2032) Table 267. Middle East and Africa Antihyperuricemic Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 268. Middle East and Africa Antihyperuricemic Agents Market Size by Country (2021-2026) & (US$ Million) Table 269. Middle East and Africa Antihyperuricemic Agents Market Share by Country (2021-2026) Table 270. Middle East and Africa Antihyperuricemic Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 271. Middle East and Africa Antihyperuricemic Agents Market Share Forecast by Country (2027-2032) Table 272. Key Raw Materials Table 273. Raw Materials Key Suppliers Table 274. Antihyperuricemic Agents Distributors List Table 275. Antihyperuricemic Agents Customers List Table 276. Research Programs/Design for This Report Table 277. Authors List of This Report Table 278. Secondary Sources Table 279. Primary Sources List of Figures Figure 1. Antihyperuricemic Agents Image Figure 2. Global Antihyperuricemic Agents Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antihyperuricemic Agents Market Size (2021-2032) & (US$ Million) Figure 4. Global Antihyperuricemic Agents Sales (2021-2032) & (K Units) Figure 5. Inhibit Uric Acid Production Agents Image Figure 6. Global Inhibit Uric Acid Production Agents Sales YoY Growth (2021-2032) & (K Units) Figure 7. Promote Uric Acid Excretion Agents Image Figure 8. Global Promote Uric Acid Excretion Agents Sales YoY Growth (2021-2032) & (K Units) Figure 9. Others Image Figure 10. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Antihyperuricemic Agents Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Antihyperuricemic Agents Market Share by Type 2025 VS 2032 Figure 13. North America Antihyperuricemic Agents Sales Market Share in Volume by Type in 2025 Figure 14. North America Antihyperuricemic Agents Sales Market Share in Value by Type in 2025 Figure 15. Europe Antihyperuricemic Agents Sales Market Share in Volume by Type in 2025 Figure 16. Europe Antihyperuricemic Agents Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Antihyperuricemic Agents Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Antihyperuricemic Agents Sales Market Share in Value by Type in 2025 Figure 19. Latin America Antihyperuricemic Agents Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Antihyperuricemic Agents Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Antihyperuricemic Agents Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Antihyperuricemic Agents Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Antihyperuricemic Agents Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Retail Pharmacies Image Figure 26. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 27. Online Pharmacies Image Figure 28. Global Online Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 29. Hospital Pharmacies Image Figure 30. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global Antihyperuricemic Agents Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Antihyperuricemic Agents Market Share by Application 2025 VS 2032 Figure 33. North America Antihyperuricemic Agents Sales Market Share in Volume by Application in 2025 Figure 34. North America Antihyperuricemic Agents Sales Market Share in Value by Application in 2025 Figure 35. Europe Antihyperuricemic Agents Sales Market Share in Volume by Application in 2025 Figure 36. Europe Antihyperuricemic Agents Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Antihyperuricemic Agents Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Antihyperuricemic Agents Sales Market Share in Value by Application in 2025 Figure 39. Latin America Antihyperuricemic Agents Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Antihyperuricemic Agents Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Antihyperuricemic Agents Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Antihyperuricemic Agents Sales Market Share in Value by Application in 2025 Figure 43. North America Antihyperuricemic Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America Antihyperuricemic Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Antihyperuricemic Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Antihyperuricemic Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Antihyperuricemic Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe Antihyperuricemic Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Antihyperuricemic Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Antihyperuricemic Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Antihyperuricemic Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific Antihyperuricemic Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Antihyperuricemic Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Antihyperuricemic Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Antihyperuricemic Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America Antihyperuricemic Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Antihyperuricemic Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Antihyperuricemic Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Antihyperuricemic Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa Antihyperuricemic Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Antihyperuricemic Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Antihyperuricemic Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Antihyperuricemic Agents Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Antihyperuricemic Agents Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Inhibit Uric Acid Production Agents
  • Promote Uric Acid Excretion Agents
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Accord Healthcare
  • ALP Pharm
  • APOTEX
  • Casper Pharma
  • Dr. Reddys Laboratories
  • Gentec Pharmaceutical Group
  • Hikma
  • Indoco Remedies
  • Ipca Laboratories
  • Lupin
  • Medinova
  • NorthStar Healthcare
  • Odan Laboratories
  • Rhea Pharmaceutical
  • TEIJIN
  • Waterstone Pharmaceuticals
  • West Ward Pharmaceuticals
  • Wockhardt
  • Zydus Pharmaceuticals
  • Beijing Jialin Pharmaceutical
  • Hangzhou Zhuyangxin Pharmaceutical
  • Jiangsu Hengrui Medicine
  • Jiangsu Wanbang Biopharmaceuticals
  • KPC Pharmaceuticals
  • Mylan
  • Sun Pharmaceutical
  • Teva
  • Tonghua Limin
  • Takeda Pharmaceuticals
  • YiChang HEC ChangJiang Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antihyperuricemic Agents Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Antihyperuricemic Agents Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Antihyperuricemic Agents Market by Type
  6. 1.3.1 Inhibit Uric Acid Production Agents
  7. 1.3.2 Promote Uric Acid Excretion Agents
  8. 1.3.3 Others
  9. 1.4 Global Antihyperuricemic Agents Market Size by Type
  10. 1.4.1 Global Antihyperuricemic Agents Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Antihyperuricemic Agents Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Antihyperuricemic Agents Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Antihyperuricemic Agents Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Antihyperuricemic Agents Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Antihyperuricemic Agents Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Antihyperuricemic Agents Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Antihyperuricemic Agents Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Antihyperuricemic Agents Industry Trends
  2. 2.2 Antihyperuricemic Agents Industry Drivers
  3. 2.3 Antihyperuricemic Agents Industry Opportunities and Challenges
  4. 2.4 Antihyperuricemic Agents Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Antihyperuricemic Agents Revenue (2021-2026)
  2. 3.2 Global Top Players by Antihyperuricemic Agents Sales (2021-2026)
  3. 3.3 Global Top Players by Antihyperuricemic Agents Price (2021-2026)
  4. 3.4 Global Antihyperuricemic Agents Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antihyperuricemic Agents Major Company Production Sites & Headquarters
  6. 3.6 Global Antihyperuricemic Agents Company, Product Type & Application
  7. 3.7 Global Antihyperuricemic Agents Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antihyperuricemic Agents Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antihyperuricemic Agents Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antihyperuricemic Agents Tier 1, Tier 2, and Tier 3
4 Antihyperuricemic Agents Regional Status and Outlook
  1. 4.1 Global Antihyperuricemic Agents Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Antihyperuricemic Agents Historic Market Size by Region
  3. 4.2.1 Global Antihyperuricemic Agents Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Antihyperuricemic Agents Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Antihyperuricemic Agents Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Antihyperuricemic Agents Forecasted Market Size by Region
  7. 4.3.1 Global Antihyperuricemic Agents Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Antihyperuricemic Agents Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Antihyperuricemic Agents Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Antihyperuricemic Agents by Application
  1. 5.1 Antihyperuricemic Agents Market by Application
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Antihyperuricemic Agents Market Size by Application
  6. 5.2.1 Global Antihyperuricemic Agents Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Antihyperuricemic Agents Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Antihyperuricemic Agents Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Antihyperuricemic Agents Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Antihyperuricemic Agents Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Antihyperuricemic Agents Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Antihyperuricemic Agents Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Antihyperuricemic Agents Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Accord Healthcare
  2. 6.1.1 Accord Healthcare Company Information
  3. 6.1.2 Accord Healthcare Business Overview
  4. 6.1.3 Accord Healthcare Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Accord Healthcare Antihyperuricemic Agents Product Portfolio
  6. 6.1.5 Accord Healthcare Recent Developments
  7. 6.2 ALP Pharm
  8. 6.2.1 ALP Pharm Company Information
  9. 6.2.2 ALP Pharm Business Overview
  10. 6.2.3 ALP Pharm Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 ALP Pharm Antihyperuricemic Agents Product Portfolio
  12. 6.2.5 ALP Pharm Recent Developments
  13. 6.3 APOTEX
  14. 6.3.1 APOTEX Company Information
  15. 6.3.2 APOTEX Business Overview
  16. 6.3.3 APOTEX Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 APOTEX Antihyperuricemic Agents Product Portfolio
  18. 6.3.5 APOTEX Recent Developments
  19. 6.4 Casper Pharma
  20. 6.4.1 Casper Pharma Company Information
  21. 6.4.2 Casper Pharma Business Overview
  22. 6.4.3 Casper Pharma Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Casper Pharma Antihyperuricemic Agents Product Portfolio
  24. 6.4.5 Casper Pharma Recent Developments
  25. 6.5 Dr. Reddys Laboratories
  26. 6.5.1 Dr. Reddys Laboratories Company Information
  27. 6.5.2 Dr. Reddys Laboratories Business Overview
  28. 6.5.3 Dr. Reddys Laboratories Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Dr. Reddys Laboratories Antihyperuricemic Agents Product Portfolio
  30. 6.5.5 Dr. Reddys Laboratories Recent Developments
  31. 6.6 Gentec Pharmaceutical Group
  32. 6.6.1 Gentec Pharmaceutical Group Company Information
  33. 6.6.2 Gentec Pharmaceutical Group Business Overview
  34. 6.6.3 Gentec Pharmaceutical Group Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Gentec Pharmaceutical Group Antihyperuricemic Agents Product Portfolio
  36. 6.6.5 Gentec Pharmaceutical Group Recent Developments
  37. 6.7 Hikma
  38. 6.7.1 Hikma Company Information
  39. 6.7.2 Hikma Business Overview
  40. 6.7.3 Hikma Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Hikma Antihyperuricemic Agents Product Portfolio
  42. 6.7.5 Hikma Recent Developments
  43. 6.8 Indoco Remedies
  44. 6.8.1 Indoco Remedies Company Information
  45. 6.8.2 Indoco Remedies Business Overview
  46. 6.8.3 Indoco Remedies Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Indoco Remedies Antihyperuricemic Agents Product Portfolio
  48. 6.8.5 Indoco Remedies Recent Developments
  49. 6.9 Ipca Laboratories
  50. 6.9.1 Ipca Laboratories Company Information
  51. 6.9.2 Ipca Laboratories Business Overview
  52. 6.9.3 Ipca Laboratories Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Ipca Laboratories Antihyperuricemic Agents Product Portfolio
  54. 6.9.5 Ipca Laboratories Recent Developments
  55. 6.10 Lupin
  56. 6.10.1 Lupin Company Information
  57. 6.10.2 Lupin Business Overview
  58. 6.10.3 Lupin Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Lupin Antihyperuricemic Agents Product Portfolio
  60. 6.10.5 Lupin Recent Developments
  61. 6.11 Medinova
  62. 6.11.1 Medinova Company Information
  63. 6.11.2 Medinova Business Overview
  64. 6.11.3 Medinova Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Medinova Antihyperuricemic Agents Product Portfolio
  66. 6.11.5 Medinova Recent Developments
  67. 6.12 NorthStar Healthcare
  68. 6.12.1 NorthStar Healthcare Company Information
  69. 6.12.2 NorthStar Healthcare Business Overview
  70. 6.12.3 NorthStar Healthcare Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 NorthStar Healthcare Antihyperuricemic Agents Product Portfolio
  72. 6.12.5 NorthStar Healthcare Recent Developments
  73. 6.13 Odan Laboratories
  74. 6.13.1 Odan Laboratories Company Information
  75. 6.13.2 Odan Laboratories Business Overview
  76. 6.13.3 Odan Laboratories Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Odan Laboratories Antihyperuricemic Agents Product Portfolio
  78. 6.13.5 Odan Laboratories Recent Developments
  79. 6.14 Rhea Pharmaceutical
  80. 6.14.1 Rhea Pharmaceutical Company Information
  81. 6.14.2 Rhea Pharmaceutical Business Overview
  82. 6.14.3 Rhea Pharmaceutical Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Rhea Pharmaceutical Antihyperuricemic Agents Product Portfolio
  84. 6.14.5 Rhea Pharmaceutical Recent Developments
  85. 6.15 TEIJIN
  86. 6.15.1 TEIJIN Company Information
  87. 6.15.2 TEIJIN Business Overview
  88. 6.15.3 TEIJIN Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 TEIJIN Antihyperuricemic Agents Product Portfolio
  90. 6.15.5 TEIJIN Recent Developments
  91. 6.16 Waterstone Pharmaceuticals
  92. 6.16.1 Waterstone Pharmaceuticals Company Information
  93. 6.16.2 Waterstone Pharmaceuticals Business Overview
  94. 6.16.3 Waterstone Pharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Waterstone Pharmaceuticals Antihyperuricemic Agents Product Portfolio
  96. 6.16.5 Waterstone Pharmaceuticals Recent Developments
  97. 6.17 West Ward Pharmaceuticals
  98. 6.17.1 West Ward Pharmaceuticals Company Information
  99. 6.17.2 West Ward Pharmaceuticals Business Overview
  100. 6.17.3 West Ward Pharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 West Ward Pharmaceuticals Antihyperuricemic Agents Product Portfolio
  102. 6.17.5 West Ward Pharmaceuticals Recent Developments
  103. 6.18 Wockhardt
  104. 6.18.1 Wockhardt Company Information
  105. 6.18.2 Wockhardt Business Overview
  106. 6.18.3 Wockhardt Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Wockhardt Antihyperuricemic Agents Product Portfolio
  108. 6.18.5 Wockhardt Recent Developments
  109. 6.19 Zydus Pharmaceuticals
  110. 6.19.1 Zydus Pharmaceuticals Company Information
  111. 6.19.2 Zydus Pharmaceuticals Business Overview
  112. 6.19.3 Zydus Pharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Zydus Pharmaceuticals Antihyperuricemic Agents Product Portfolio
  114. 6.19.5 Zydus Pharmaceuticals Recent Developments
  115. 6.20 Beijing Jialin Pharmaceutical
  116. 6.20.1 Beijing Jialin Pharmaceutical Company Information
  117. 6.20.2 Beijing Jialin Pharmaceutical Business Overview
  118. 6.20.3 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Portfolio
  120. 6.20.5 Beijing Jialin Pharmaceutical Recent Developments
  121. 6.21 Hangzhou Zhuyangxin Pharmaceutical
  122. 6.21.1 Hangzhou Zhuyangxin Pharmaceutical Company Information
  123. 6.21.2 Hangzhou Zhuyangxin Pharmaceutical Business Overview
  124. 6.21.3 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Portfolio
  126. 6.21.5 Hangzhou Zhuyangxin Pharmaceutical Recent Developments
  127. 6.22 Jiangsu Hengrui Medicine
  128. 6.22.1 Jiangsu Hengrui Medicine Company Information
  129. 6.22.2 Jiangsu Hengrui Medicine Business Overview
  130. 6.22.3 Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Portfolio
  132. 6.22.5 Jiangsu Hengrui Medicine Recent Developments
  133. 6.23 Jiangsu Wanbang Biopharmaceuticals
  134. 6.23.1 Jiangsu Wanbang Biopharmaceuticals Company Information
  135. 6.23.2 Jiangsu Wanbang Biopharmaceuticals Business Overview
  136. 6.23.3 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Portfolio
  138. 6.23.5 Jiangsu Wanbang Biopharmaceuticals Recent Developments
  139. 6.24 KPC Pharmaceuticals
  140. 6.24.1 KPC Pharmaceuticals Company Information
  141. 6.24.2 KPC Pharmaceuticals Business Overview
  142. 6.24.3 KPC Pharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 KPC Pharmaceuticals Antihyperuricemic Agents Product Portfolio
  144. 6.24.5 KPC Pharmaceuticals Recent Developments
  145. 6.25 Mylan
  146. 6.25.1 Mylan Company Information
  147. 6.25.2 Mylan Business Overview
  148. 6.25.3 Mylan Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 Mylan Antihyperuricemic Agents Product Portfolio
  150. 6.25.5 Mylan Recent Developments
  151. 6.26 Sun Pharmaceutical
  152. 6.26.1 Sun Pharmaceutical Company Information
  153. 6.26.2 Sun Pharmaceutical Business Overview
  154. 6.26.3 Sun Pharmaceutical Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  155. 6.26.4 Sun Pharmaceutical Antihyperuricemic Agents Product Portfolio
  156. 6.26.5 Sun Pharmaceutical Recent Developments
  157. 6.27 Teva
  158. 6.27.1 Teva Company Information
  159. 6.27.2 Teva Business Overview
  160. 6.27.3 Teva Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  161. 6.27.4 Teva Antihyperuricemic Agents Product Portfolio
  162. 6.27.5 Teva Recent Developments
  163. 6.28 Tonghua Limin
  164. 6.28.1 Tonghua Limin Company Information
  165. 6.28.2 Tonghua Limin Business Overview
  166. 6.28.3 Tonghua Limin Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  167. 6.28.4 Tonghua Limin Antihyperuricemic Agents Product Portfolio
  168. 6.28.5 Tonghua Limin Recent Developments
  169. 6.29 Takeda Pharmaceuticals
  170. 6.29.1 Takeda Pharmaceuticals Company Information
  171. 6.29.2 Takeda Pharmaceuticals Business Overview
  172. 6.29.3 Takeda Pharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  173. 6.29.4 Takeda Pharmaceuticals Antihyperuricemic Agents Product Portfolio
  174. 6.29.5 Takeda Pharmaceuticals Recent Developments
  175. 6.30 YiChang HEC ChangJiang Pharmaceutical
  176. 6.30.1 YiChang HEC ChangJiang Pharmaceutical Company Information
  177. 6.30.2 YiChang HEC ChangJiang Pharmaceutical Business Overview
  178. 6.30.3 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales, Revenue and Gross Margin (2021-2026)
  179. 6.30.4 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Portfolio
  180. 6.30.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments
7 North America by Country
  1. 7.1 North America Antihyperuricemic Agents Sales by Country
  2. 7.1.1 North America Antihyperuricemic Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Antihyperuricemic Agents Sales by Country (2021-2026)
  4. 7.1.3 North America Antihyperuricemic Agents Sales Forecast by Country (2027-2032)
  5. 7.2 North America Antihyperuricemic Agents Market Size by Country
  6. 7.2.1 North America Antihyperuricemic Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Antihyperuricemic Agents Market Size by Country (2021-2026)
  8. 7.2.3 North America Antihyperuricemic Agents Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Antihyperuricemic Agents Sales by Country
  2. 8.1.1 Europe Antihyperuricemic Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Antihyperuricemic Agents Sales by Country (2021-2026)
  4. 8.1.3 Europe Antihyperuricemic Agents Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Antihyperuricemic Agents Market Size by Country
  6. 8.2.1 Europe Antihyperuricemic Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Antihyperuricemic Agents Market Size by Country (2021-2026)
  8. 8.2.3 Europe Antihyperuricemic Agents Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Antihyperuricemic Agents Sales by Country
  2. 9.1.1 Asia-Pacific Antihyperuricemic Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Antihyperuricemic Agents Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Antihyperuricemic Agents Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Antihyperuricemic Agents Market Size by Country
  6. 9.2.1 Asia-Pacific Antihyperuricemic Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Antihyperuricemic Agents Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Antihyperuricemic Agents Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Antihyperuricemic Agents Sales by Country
  2. 10.1.1 South America Antihyperuricemic Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Antihyperuricemic Agents Sales by Country (2021-2026)
  4. 10.1.3 South America Antihyperuricemic Agents Sales Forecast by Country (2027-2032)
  5. 10.2 South America Antihyperuricemic Agents Market Size by Country
  6. 10.2.1 South America Antihyperuricemic Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Antihyperuricemic Agents Market Size by Country (2021-2026)
  8. 10.2.3 South America Antihyperuricemic Agents Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Antihyperuricemic Agents Sales by Country
  2. 11.1.1 Middle East and Africa Antihyperuricemic Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Antihyperuricemic Agents Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Antihyperuricemic Agents Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Antihyperuricemic Agents Market Size by Country
  6. 11.2.1 Middle East and Africa Antihyperuricemic Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Antihyperuricemic Agents Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Antihyperuricemic Agents Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Antihyperuricemic Agents Value Chain Analysis
  2. 12.1.1 Antihyperuricemic Agents Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Antihyperuricemic Agents Production Mode & Process
  7. 12.2 Antihyperuricemic Agents Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Antihyperuricemic Agents Distributors
  10. 12.2.3 Antihyperuricemic Agents Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst